Agios Pharmaceuticals | AGIO - Selling And Administration Expenses


Agios Pharmaceuticals reported $41.27M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Arrowhead Research USD 37.18M 6.23M Sep/2025
Astellas Pharma JPY 206.84B 9.84B Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Exelixis USD 103.13M 9.8M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Merck USD 2.63B 0 Sep/2025
Moderna USD 268M 38M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025